Forsyth C - Search Results

1

Delayed-onset heparin-induced thrombocytopenia complicated by arterial and venous thromboses.

Balendran S, Harrison A, Morel-Kopp MC, Ward C, Forsyth C. Balendran S, et al. Among authors: forsyth c. Intern Med J. 2018 Jan;48(1):98-100. doi: 10.1111/imj.13665. Intern Med J. 2018. PMID: 29314517 No abstract available.

2

Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in Chronic Lymphocytic Leukaemia.

Crassini KR, Zhang E, Balendran S, Freeman JA, Best OG, Forsyth CJ, Mackinlay NJ, Han P, Stevenson WS, Mulligan SP. Crassini KR, et al. Br J Haematol. 2018 Apr;181(1):97-101. doi: 10.1111/bjh.15146. Epub 2018 Feb 21. Br J Haematol. 2018. PMID: 29468645 Free article.

3

Recommendations for the use of pegylated interferon-α in the treatment of classical myeloproliferative neoplasms.

Forsyth CJ, Chan WH, Grigg AP, Cook NC, Lane SW, Burbury KL, Perkins AC, Ross DM. Forsyth CJ, et al. Intern Med J. 2019 Aug;49(8):948-954. doi: 10.1111/imj.14154. Intern Med J. 2019. PMID: 30411442 Review.

4

Subacute combined degeneration of the spinal cord due to pernicious anaemia with an erroneously normal active B12 level.

Halliwell N, Forsyth C, Taylor N, Mangalasseril S, Sturm J. Halliwell N, et al. Among authors: forsyth c. Intern Med J. 2021 Jul;51(7):1184-1185. doi: 10.1111/imj.15411. Intern Med J. 2021. PMID: 34278689 No abstract available.

5

Variable incidence of myeloproliferative neoplasms in Australia.

Forsyth C, Blennerhassett R, Jagger J, Myers J, Erber W. Forsyth C, et al. Intern Med J. 2021 Nov;51(11):1979-1980. doi: 10.1111/imj.15565. Intern Med J. 2021. PMID: 34796634 No abstract available.

6

Non-anaemic iron deficiency.

Balendran S, Forsyth C. Balendran S, et al. Among authors: forsyth c. Aust Prescr. 2021 Dec;44(6):193-196. doi: 10.18773/austprescr.2021.052. Epub 2021 Dec 1. Aust Prescr. 2021. PMID: 35002031 Free PMC article. Review.

7

Management of acute vascular graft thrombosis associated with HIT syndrome: a case report.

Wilson M, Forsyth C, McGahan T, White G. Wilson M, et al. Among authors: forsyth c. Aust N Z J Surg. 1997 May;67(5):302-3. doi: 10.1111/j.1445-2197.1997.tb01973.x. Aust N Z J Surg. 1997. PMID: 9152167 No abstract available.

8

A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.

Ho PJ, Bajel A, Burbury K, Dunlop L, Durrant S, Forsyth C, Perkins AC, Ross DM. Ho PJ, et al. Among authors: forsyth c. Intern Med J. 2017 Mar;47(3):262-268. doi: 10.1111/imj.13341. Intern Med J. 2017. PMID: 28260257

9

Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea.

Douglas G, Harrison C, Forsyth C, Bennett M, Stevenson W, Hounsell J, Ratnasingam S, Ritchie D, Ross DM, Grigg A. Douglas G, et al. Among authors: forsyth c. Leuk Lymphoma. 2017 Jan;58(1):89-95. doi: 10.1080/10428194.2016.1187269. Epub 2016 Jul 25. Leuk Lymphoma. 2017. PMID: 27454522

10

When should iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload?

Bird RJ, Kenealy M, Forsyth C, Wellwood J, Leahy MF, Seymour JF, To LB. Bird RJ, et al. Among authors: forsyth c. Intern Med J. 2012 Apr;42(4):450-5. doi: 10.1111/j.1445-5994.2012.02734.x. Intern Med J. 2012. PMID: 22498118

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

476 results

Search Page

Filters